HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Anne Sieben Selected Research

Peptides (Polypeptides)

11/2022Associating Alzheimer's disease pathology with its cerebrospinal fluid biomarkers.
11/2020Amyloid-β1-43 cerebrospinal fluid levels and the interpretation of APP, PSEN1 and PSEN2 mutations.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Anne Sieben Research Topics

Disease

16Alzheimer Disease (Alzheimer's Disease)
10/2023 - 12/2015
9Frontotemporal Lobar Degeneration (Degeneration, Frontotemporal Lobar)
10/2023 - 09/2012
7Frontotemporal Dementia (Semantic Dementia)
10/2023 - 11/2015
5Dementia (Dementias)
01/2023 - 07/2017
3Amyotrophic Lateral Sclerosis (Lou Gehrig's Disease)
01/2021 - 11/2015
2Tauopathies
07/2022 - 12/2018
2Primary Progressive Aphasia
01/2022 - 12/2018
2Parkinson Disease (Parkinson's Disease)
12/2021 - 01/2017
2Proteostasis Deficiencies
01/2018 - 09/2012
1Prion Diseases (Transmissible Spongiform Encephalopathies)
09/2023
1Inflammation (Inflammations)
07/2023
1Neuroinflammatory Diseases
07/2023
1Amyloid Plaque
11/2022
1Mitochondrial Diseases (Mitochondrial Disease)
07/2022
1Seizures (Absence Seizure)
07/2022
1Creutzfeldt-Jakob Syndrome (Creutzfeldt-Jakob Disease)
12/2021
1Lewy Body Disease (Lewy Body Dementia)
12/2021
1Neurodegenerative Diseases (Neurodegenerative Disease)
01/2021
1Death (Near-Death Experience)
01/2019
1Chromosome Inversion (Chromosomal Inversion)
01/2019
1Broca Aphasia (Expressive Aphasia)
12/2018
1Atrophy
01/2018
1Cognitive Dysfunction
01/2017
1Cerebrovascular Disorders (Cerebrovascular Occlusion)
01/2016
1Neurobehavioral Manifestations
01/2016
1Disease Susceptibility (Diathesis)
09/2014
1Sarcoma (Soft Tissue Sarcoma)
09/2012
1Atherosclerosis
03/2012
1Neoplasms (Cancer)
03/2012
1Progressive Supranuclear Palsy (Steele Richardson Olszewski Syndrome)
09/2009
1Glioblastoma (Glioblastoma Multiforme)
05/2007
1Multiple System Atrophy
04/2006

Drug/Important Bio-Agent (IBA)

13Biomarkers (Surrogate Marker)IBA
01/2023 - 09/2012
6Proteins (Proteins, Gene)FDA Link
07/2023 - 09/2012
5DNA-Binding Proteins (DNA Binding Protein)IBA
10/2023 - 09/2012
5Amyloid (Amyloid Fibrils)IBA
01/2023 - 01/2018
3ProgranulinsIBA
10/2023 - 11/2015
2Microtubule-Associated Proteins (Microtubule-Associated Protein 2)IBA
01/2023 - 09/2012
2Peptides (Polypeptides)IBA
11/2022 - 11/2020
1Prion ProteinsIBA
09/2023
1Toll-Like Receptor 9IBA
07/2023
1CytokinesIBA
07/2023
1Protein AggregatesIBA
07/2023
1ProteomeIBA
01/2023
1Protein Isoforms (Isoforms)IBA
01/2023
1Threonine (L-Threonine)FDA Link
11/2022
1Amino AcidsFDA Link
11/2022
1tau Proteins (tau Protein)IBA
11/2022
1NG-Nitroarginine Methyl Ester (L-NAME)IBA
07/2022
1Nitric Oxide Synthase (NO Synthase)IBA
07/2022
1G-Protein-Coupled Receptors (Receptors, G Protein Coupled)IBA
07/2022
1NeurograninIBA
12/2021
1SynucleinsIBA
12/2021
1PresenilinsIBA
11/2020
1Dipeptidyl-Peptidases and Tripeptidyl-PeptidasesIBA
01/2019
1THK5351IBA
12/2018
1Neurofilament ProteinsIBA
01/2018
1sortilinIBA
01/2018
1GranulinsIBA
01/2018
1Amyloid beta-PeptidesIBA
01/2018
1EpitopesIBA
07/2017
1Nonsense Codon (Nonsense Mutation)IBA
01/2017
1Neurotransmitter Agents (Neurotransmitter)IBA
01/2016
1Psychotropic Drugs (Psychoactive Drugs)IBA
01/2016
1UbiquitinIBA
01/2016
1Apolipoproteins E (ApoE)IBA
01/2016
1Cystatin CIBA
01/2016
1FilaminsIBA
11/2015
1hyperforinIBA
05/2007
1Antidepressive Agents (Antidepressants)IBA
05/2007
1hyperosideIBA
05/2007
1Desipramine (Pertofrane)FDA LinkGeneric
05/2007

Therapy/Procedure

1Therapeutics
01/2022
1Euthanasia (Mercy Killing)
01/2019
1Palliative Care (Palliative Therapy)
01/2019
1Radiotherapy
03/2012
1Transcranial Magnetic Stimulation
09/2009
1Deep Brain Stimulation
04/2006